Modulation of Gut Microbiota With NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes Mellitus
Latest Information Update: 15 Oct 2024
Price :
$35 *
At a glance
- Drugs NBT-NM108 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms COVGUT20
- Sponsors Notitia Biotechnologies
- 13 Nov 2023 Status changed from active, no longer recruiting to completed.
- 09 Jun 2022 Planned End Date changed from 1 Jan 2022 to 1 Dec 2022.
- 09 Jun 2022 Status changed from recruiting to active, no longer recruiting.